Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05487547 · ClinicalTrials.gov registry record · NA
Feasibility of IPL Combined With RF for Treatment of DED Due to MGD
A NA study, sponsored by Lumenis Be.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT05487547 is a NA study that has completed, run by Lumenis Be. The registered enrollment target is 33 participants.
The verdict
NCT05487547, a NA study, has completed, sponsored by Lumenis Be.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this single-arm pilot study is to evaluate the feasibility and safety of combination therapy of intense pulsed light (IPL) and (Radiofrequency) RF for treatment of Dry eye disease (DED) due to Meibomian gland dysfunction (MGD).
Interventions
- DEVICE IPL_RF_MGX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2022-12-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05487547
The ClinicalTrials.gov registry entry for NCT05487547 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumenis Be, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPL_RF_MGX is the first listed.
NCT05487547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05487547 about?
NCT05487547 is a clinical study titled "Feasibility of IPL Combined With RF for Treatment of DED Due to MGD". The purpose of this single-arm pilot study is to evaluate the feasibility and safety of combination therapy of intense pulsed light (IPL) and (Radiofrequency) RF for treatment of Dry eye disease (DED) due to Meibomian gland dysfunction (MGD).
What is the current status of trial NCT05487547?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2022-07-21. Estimated completion is 2022-12-28.
What interventions are being tested in trial NCT05487547?
The interventions under investigation include: IPL_RF_MGX (DEVICE).
Who is sponsoring clinical trial NCT05487547?
This trial is sponsored by Lumenis Be, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.